Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05467644Unknown

Treatment of Fracture Related Infection in Latin America.

Role: collaborator

NCT04286971Completed

Preoperative Continuous Sciatic Perineural Analgesia in Patients Undergoing Lower Limb Revascularization

Role: lead

NCT03815565Not ApplicableUnknown

Continuous Femoral Block With Levobupivacaine 0.125% or Ropivacaine 0.2% in Elderly Patients With Femoral Fractures

Role: lead

NCT00350766Phase 2Terminated

Cell Therapy in Myocardial Infarction

Role: collaborator

All 4 trials loaded